Stockscreener 앱 받기
190.02
8.54%
14.95
시장 영업 전:
188.98
-1.04
-0.55%
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Does Praxis Precision Medicines Inc. qualify in momentum factor screening2025 Volume Leaders & Weekly Return Optimization Alerts - newser.com
What institutional flow reveals about Praxis Precision Medicines Inc.Market Movement Recap & Community Driven Trade Alerts - newser.com
Rapid Rise of PRAX: Essential Tremor Breakthrough - StocksToTrade
Praxis Precision Medicines, Inc. Announces FDA Type B Meeting for Ulixacaltamide - TradingView
12 Reddit Stocks That Will Go to the Moon - Insider Monkey
Applying big data sentiment scoring on Praxis Precision Medicines Inc.Stop Loss & Verified Stock Trade Ideas - newser.com
Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq
Published on: 2025-10-20 08:35:46 - newser.com
Wedbush lifts Praxis Precision Medicines PT; shares down - TradingView
Largest borrow rate increases among liquid names - TipRanks
Published on: 2025-10-20 07:35:45 - newser.com
Wedbush Boosts Price Target on Praxis Precision Medicines to $73 From $33, Keeps Underperform Rating - MarketScreener
Praxis Precision Medicines Announces Underwritten Offering - TradingView
Praxis surges after late-stage trial success for movement disorder therapy - MSN
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN
Is Praxis Precision Medicines Inc. stock undervalued vs historical averagesPortfolio Return Summary & Safe Capital Growth Trade Ideas - nchmf.gov.vn
Praxis Precision Medicines (PRAX) Is Up 256.7% After Positive Phase 3 Results for Essential Tremor Drug - simplywall.st
Is Praxis Precision Medicines Inc. stock a buy on dipsJuly 2025 Fed Impact & Verified Stock Trade Ideas - nchmf.gov.vn
Major Investment Alert: Adage Capital’s Bold Move in Praxis Precision Medicines! - TipRanks
Is Praxis Precision Medicines Inc. stock cheap at current valuationJuly 2025 Sector Moves & Long-Term Safe Investment Ideas - nchmf.gov.vn
PRAX underwritten deal: $157/share, warrants; $567M net proceeds - Stock Titan
PRAX prices common stock and pre-funded warrants; proceeds ~$493.0M - Stock Titan
Praxis Precision Medicines, Inc.Common Stock (NQ: PRAX - FinancialContent
Can Praxis Precision Medicines Keep Climbing? - timothysykes.com
[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity - Stock Titan
Praxis Shares Skyrocket: Too Late to Buy? - StocksToTrade
Praxis Precision Medicines: A New High? - timothysykes.com
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday - Benzinga
Praxis Precision (PRAX) Triples on Stellar Drug Trial Results - Insider Monkey
Ulixacaltamide Trial Success Propels PRAX - StocksToTrade
Boston biotech raises $525M after stock triples on late-stage drug trial results - The Business Journals
Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? - Yahoo Finance
Praxis Precision Medicines (PRAX) Stock Soars After Essential Tremor Drug Success - parameter.io
Praxis Precision Medicines, Inc. (PRAX) Stock: Soars 183% Following $525M Public Offering Announcement - parameter.io
HC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Deutsche Bank Boosts Price Target on Praxis Precision Medicines to $280 From $65, Keeps Buy Rating - MarketScreener
Praxis Precision Medicines extends rally after $525 mln stock sale - TradingView
Praxis: Back From The Dead, Ulixacaltamide Returns In Essential Tremor With Caveats (PRAX) - Seeking Alpha
Praxis Precision Medicines Reaches Analyst Target Price - Nasdaq
Praxis Precision Medicines prices $525 million public offering By Investing.com - Investing.com Nigeria
Why Praxis Precision Medicines Stock Skyrocketed - TipRanks
Praxis Precision Stock Extends Rally Premarket As Wall Street Turns Hyper-Bullish After Essential Tremor Trial Win - Stocktwits
Praxis Precision Medicines Prices $525 Million Share Offering - MarketScreener
Praxis Precision Medicines prices $525 million public offering - Investing.com India
Praxis Precision Medicines (PRAX) Aims to Raise $525M Through Pu - GuruFocus
Praxis Precision Medicines prices $525M public offering - MSN
A Look at Praxis Precision Medicines (PRAX) Valuation Following Positive Phase 3 Results in Essential Tremor - simplywall.st
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering - Investing News Network
Praxis Precision Medicines Announces Pricing of $525 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
$525M Offering — Praxis Precision Medicines Prices Common Stock at $157 per Share - Stock Titan
Praxis Precision Medicines stock soars as Oppenheimer raises price target on trial success - Investing.com Philippines
Baird raises Praxis Precision Medicines stock price target to $275 on positive trial results By Investing.com - Investing.com South Africa
Why This Biotech Stock Exploded 184% to a Three-Year High - TipRanks
2.32%
1.34%
자본화:
|
볼륨(24시간):